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for IRIS have been identiﬁed, such as low CD4 count pre-ART initiation
and the presence of a disseminated opportunistic infection, there are
no biomarkers that predict which patients will develop IRIS. The identiﬁ-
cation of biomarkers for IRIS prediction may help elucidate the mecha-
nism of IRIS pathogenesis, which may in turn facilitate the developmentIn the last 10–20 years, access to antiretroviral therapy (ART) has
would beneﬁt from speciﬁc preventative strategies to be identiﬁed.
A large number of investigations have addressed the roles played byimproved worldwide, resulting in substantial reduction in HIV-
associated mortality and increased life expectancy, especially in low
andmiddle-income countries. However, immune reconstitution inﬂam-
matory syndrome (IRIS), the clinical deterioration in patients with HIV
initiating ART, is a common complication of ART initiation. Themanifes-
tations of IRIS depend on the type of opportunistic infection.WithHIV-1
as the strongest predisposing factor to tuberculosis (TB) and TB as the
commonest cause of death in HIV-1 infected persons in Africa, the oth-
erwise beneﬁcial dual therapy for HIV-1 and TB is frequently complicat-
ed by the occurrence of TB-immune reconstitution inﬂammatory
syndrome (TB-IRIS) (Walker et al., 2015). Two forms of TB-IRIS are rec-
ognized: paradoxical, which occurs in patients established on anti-
tuberculosis therapy before ART, but who develop recurrent or new
TB symptoms and clinical features after ART initiation; and unmasking
TB-IRIS in patients not receiving treatment for TB when ART is started,
but who present with active TB within 3 months of starting ART
(Meintjes et al., 2008). Paradoxical TB-IRIS affects approximately
15.7% of all HIV-1-infected patients commencing ARTwhile on TB treat-
ment, and up to 52% in some populations, causing considerablemorbid-
ity and mortality (Namale et al., 2015).
While the clinical features are relatively well-described, speciﬁc di-
agnostic tools and treatments for TB-IRIS are lacking. The diagnosis of
IRIS is clinical, and excluding other causes for a clinical deterioration,
such as other opportunistic infections and drug-resistance, ism.2016.01.016.
andMolecularMedicineRoom
25, Republic of South Africa.
. This is an open access article underof speciﬁc therapies and additionally, allow high-risk patients that
different aspects of the immune response in contributing to TB-IRIS
pathogenesis, reviewed in Lai et al. (2015a). A recent unbiased whole-
blood transcriptomic proﬁling of HIV-TB co-infected patients commenc-
ing ART showed that inﬂammation in TB-IRIS is driven by innate im-
mune signaling and activation of the inﬂammasome, which triggers
the activation of transcription factors leading to hypercytokinemia,
resulting in systemic inﬂammation (Lai et al., 2015b). Other recent
work also suggests that extracellular matrix destruction by matrix me-
talloproteinases may play a role in paradoxical TB-IRIS (Tadokera
et al., 2014; Shruthi Ravimohan, 2015). Immunosuppressive corticoste-
roid therapy improves symptoms and reduces hospital admissions but
is not without adverse events, and is potentially detrimental in cases
of drug-resistant TB (Meintjes et al., 2010). Therefore therapeutic strat-
egies that offer greater immune speciﬁcity should be explored.
The CADIRIS study, a double-blind, randomized, placebo-controlled
trial, investigated the use of maraviroc (a CCR5 antagonist) for IRIS pre-
vention, based on the hypothesis that inﬂammatory cytokines and
chemokines mediate the inﬂux of CCR5-expressing immune cells in
IRIS and CCR5 blockadewould prevent these inﬂammatory cells leaving
the circulation, reducing local inﬂammatory reactions leading to IRIS.
The study recruited HIV-infected participants with advanced immuno-
suppression (CD4 count b100/μl) from ﬁve clinical sites in Mexico and
one in South Africa and followed them for 1 year. Patientswere assigned
to receive eithermaraviroc (600mg twice daily) or placebo in addition to
ART, the primary outcome being time to an IRIS event by 24 weeks.
Maraviroc had no signiﬁcant effect on development of IRIS after ART ini-
tiation.While this CCR5 inhibitor has proven antiviral activity, safety and
tolerability as part of anART regimen, its use as an immune-modulator to
prevent IRIS appears un-warranted (Sierra-Madero et al., 2014).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
10 CommentaryWell-conducted clinical trials, even if their outcome is negative, are
an enormously valuable resource for further studies, such as identifying
correlates of risk and/or protection. In this issue of EBioMedicine,
Musselwhite and colleagues (Musselwhite et al., 2016) investigate plas-
ma biomarkers predictive of IRIS in samples banked at enrolment from
HIV-infected patients entering the CADIRIS trial. With the hypothesis
that the risk of IRIS is most likely already present before starting ART,
and can be predicted from measuring biomarkers in plasma samples
collected before startingART, they assessed twenty biomarkers in an ex-
ploratory way, and retrospectively associated them with the risk of de-
veloping IRIS. Of the 267 patients with banked plasma samples, 62
developed IRIS within 6 months of ART initiation, 31% of them TB-IRIS
speciﬁcally, within median of 13 days of ART. The results indicate that
baseline concentrations of vitamin D and higher concentrations of D-
dimer, as well as markers of T cell and monocyte activation (interfer-
on-γ and sCD14) were independently associated with risk of IRIS in
general. Vitamin D deﬁciency was prevalent. Higher vitamin D levels
were associated with protection against IRIS events, suggesting vitamin
D plays an immune-modulatory role. However, vitamin D and D-dimer
concentrations were not associated with TB-IRIS speciﬁcally, perhaps
due to lack of power for this sub-analysis. TB-IRIS was associated with
higher concentrations of CRP, sCD14, and interferon-γ and lower hemo-
globin than other forms of IRIS and these parameters were used in a
composite score to predict TB-IRIS over Other IRIS, with an area under
the curve of 0.85 (CI 0.79-0.92) on Receiver Operator Characteristics
(ROC) analysis.
The strength of this study lies in reasonable power to assess predic-
tors of IRIS and the availability of plasma samples prior to starting ART
on two different continents, contributing to the generalizability of the
ﬁndings. Interesting comparisons are drawn between TB-IRIS and
other causes of IRIS, demonstrating heterogeneity in IRIS pathophysiol-
ogy. As patients with CD4 counts ≥100/μl and those with critical illness
(e.g. severe laboratory abnormalities, CNS infections) were excluded,
generalizability of the ﬁndings to these groups is unknown. Further
work is required to conﬁrm the ﬁndings in these and other at-risk pa-
tient populations.
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